These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 11687449)

  • 1. Functional antibody activity elicited by fractional doses of Haemophilus influenzae type b conjugate vaccine (polyribosylribitol phosphate-tetanus toxoid conjugate).
    Romero-Steiner S; Fernandez J; Biltoft C; Wohl ME; Sanchez J; Feris J; Balter S; Levine OS; Carlone GM
    Clin Diagn Lab Immunol; 2001 Nov; 8(6):1115-9. PubMed ID: 11687449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economisation of vaccination against Haemophilus influenzae type b: a randomised trial of immunogenicity of fractional-dose and two-dose regimens.
    Lagos R; Valenzuela MT; Levine OS; Losonsky GA; Erazo A; Wasserman SS; Levine MM
    Lancet; 1998 May; 351(9114):1472-6. PubMed ID: 9605803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of four different doses of Haemophilus influenzae type b-tetanus toxoid conjugated vaccine, combined with diphtheria-tetanus-pertussis vaccine (DTP-Hib), in Indonesian infants.
    Punjabi NH; Richie EL; Simanjuntak CH; Harjanto SJ; Wangsasaputra F; Arjoso S; Rofiq A; Prijanto M; Julitasari ; Yela U; Herzog C; Cryz SJ
    Vaccine; 2006 Mar; 24(11):1776-85. PubMed ID: 16303216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interchangeability of Haemophilus influenzae type b vaccines in the primary series: evaluation of a two-dose mixed regimen.
    Bewley KM; Schwab JG; Ballanco GA; Daum RS
    Pediatrics; 1996 Nov; 98(5):898-904. PubMed ID: 8909483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of carrier protein priming on antibody responses to Haemophilus influenzae type b conjugate vaccines in infants.
    Granoff DM; Holmes SJ; Belshe RB; Osterholm MT; McHugh JE; Anderson EL
    JAMA; 1994 Oct; 272(14):1116-21. PubMed ID: 7933324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of PRP-T combined with DTP: excretion of capsular polysaccharide and antibody response in the immediate post-vaccination period.
    Miller MA; Meschievitz CK; Ballanco GA; Daum RS
    Pediatrics; 1995 Apr; 95(4):522-7. PubMed ID: 7700752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of two Haemophilus influenzae type b polysaccharide-tetanus toxoid conjugate vaccines (PRP-T) given with diphtheria-tetanus-pertussis vaccine to young Papua New Guinean children.
    Lehmann D; Kakazo M; Saleu G; Taime J; Javati A; Namuigi P; Alpers MP; Wegmüller B; Zellmeyer M; Fürer E; Que JU; Herzog C
    P N G Med J; 2001; 44(1-2):6-16. PubMed ID: 12418673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose response of CRM197 and tetanus toxoid-conjugated Haemophilus influenzae type b vaccines.
    Huebner RE; Nicol M; Mothupi R; Käyhty H; Mbelle N; Khomo E; Klugman KP
    Vaccine; 2004 Dec; 23(6):802-6. PubMed ID: 15542205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactogenicity and immunogenicity profiles of a novel pentavalent diphtheria-tetanus-whole cell pertussis-hepatitis B and Haemophilus influenzae type B vaccine: a randomized dose-ranging trial of the Hib tetanus-conjugate content.
    Hla KH; Thein SA; Aye A; Han HH; Bock HL; David MP; Schuerman L
    Pediatr Infect Dis J; 2006 Aug; 25(8):706-12. PubMed ID: 16874170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haemophilus influenzae type b immunization in infants in the United Kingdom: effects of diphtheria/tetanus/acellular pertussis/Hib combination vaccine, significant prematurity, and a fourth dose.
    Berrington JE; Cant AJ; Matthews JN; O'Keeffe M; Spickett GP; Fenton AC
    Pediatrics; 2006 Apr; 117(4):e717-24. PubMed ID: 16549502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants.
    Dashefsky B; Wald E; Guerra N; Byers C
    Pediatrics; 1990 Apr; 85(4 Pt 2):682-9. PubMed ID: 2107519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated levels of maternal anti-tetanus toxin antibodies do not suppress the immune response to a Haemophilus influenzae type b polyribosylphosphate-tetanus toxoid conjugate vaccine.
    Panpitpat C; Thisyakorn U; Chotpitayasunondh T; Fürer E; Que JU; Hasler T; Cryz SJ
    Bull World Health Organ; 2000; 78(3):364-71. PubMed ID: 10812736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.
    Gatchalian S; Palestroque E; De Vleeschauwer I; Han HH; Poolman J; Schuerman L; Dobbelaere K; Boutriau D
    Int J Infect Dis; 2008 May; 12(3):278-88. PubMed ID: 17981067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group.
    Schlesinger Y; Granoff DM
    JAMA; 1992 Mar; 267(11):1489-94. PubMed ID: 1538539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease.
    Eskola J; Käyhty H; Takala AK; Peltola H; Rönnberg PR; Kela E; Pekkanen E; McVerry PH; Mäkelä PH
    N Engl J Med; 1990 Nov; 323(20):1381-7. PubMed ID: 2233904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants.
    Marchant CD; Miller JM; Marshall GS; Blatter M; Aris E; Friedland LR; Boutriau D;
    Pediatr Infect Dis J; 2010 Jan; 29(1):48-52. PubMed ID: 20035207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of a Haemophilus influenzae type b-tetanus conjugate vaccine when administered separately or in combined vaccines for primary immunization in two consecutive national schedules in Turkey.
    Yüksel N; Beyazova U; Balci IF; Aksakal FN; Camurdan AD; Sahin F; Rota S
    Int J Infect Dis; 2012 May; 16(5):e354-7. PubMed ID: 22387144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Standard and alternative regimens of Haemophilus influenzae type b conjugate vaccine (polyribosylribitol phosphate-tetanus toxoid conjugate vaccine) elicit comparable antibody avidities in infants.
    Campbell JD; Lagos R; Levine MM; Losonsky GA
    Pediatr Infect Dis J; 2002 Sep; 21(9):822-6. PubMed ID: 12352802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective immunogenicity of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in children who failed to respond to prior invasive H. influenzae type b disease.
    Berthet F; Prehn A; Suter R; Ethevenaux C; Seger RA
    Pediatr Allergy Immunol; 1998 Aug; 9(3):156-60. PubMed ID: 9814731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnitude of interference after diphtheria-tetanus toxoids-acellular pertussis/Haemophilus influenzae type b capsular polysaccharide-tetanus vaccination is related to the number of doses administered.
    Daum RS; Zenko CE; Given GZ; Ballanco GA; Parikh H; Germino K
    J Infect Dis; 2001 Nov; 184(10):1293-9. PubMed ID: 11679918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.